Monocyte tissue factor induction by lipopolysaccharide (LPS): dependence on LPS-binding protein and CD14, and

K Mészáros1, S Aberle, R Dedrick

  • 1XOMA Corp, Berkeley, CA 94710.

Blood
|May 1, 1994
PubMed

Insights

Bacterial lipopolysaccharide (LPS) triggers tissue factor (TF) in monocytes, initiating coagulation in sepsis. Recombinant bactericidal/permeability-increasing protein (rBPI23) inhibits this LPS-induced TF expression, offering potential therapeutic benefits for sepsis-related coagulation disorders.

Area of Science:

  • Immunology
  • Hematology
  • Molecular Biology

Background:

  • Mononuclear phagocytes play a key role in sepsis and endotoxemia by activating coagulation.
  • Bacterial lipopolysaccharide (LPS) stimulates monocytes to synthesize tissue factor (TF), initiating the coagulation cascade.
  • TF-initiated coagulation is a critical factor in the pathophysiology of sepsis.

Purpose of the Study:

  • To elucidate the mechanism of LPS recognition by monocytes.
  • To investigate the consequent expression of TF mRNA and TF activity.
  • To evaluate the inhibitory effect of rBPI23 on LPS-induced TF expression.

Main Methods:

  • Human peripheral blood mononuclear cells or isolated monocytes were stimulated with Escherichia coli O113 LPS.
  • The role of lipopolysaccharide-binding protein (LBP) and CD14 receptors in LPS recognition was assessed.
  • TF activity, TF mRNA expression, and tumor necrosis factor expression were measured.
  • The inhibitory effects of rBPI23 were evaluated.

Main Results:

  • LPS-induced effects were dependent on the presence of lipopolysaccharide-binding protein (LBP) and CD14 receptors.
  • Recombinant bactericidal/permeability-increasing protein (rBPI23) significantly inhibited LPS-induced TF activity and mRNA expression.
  • Tumor necrosis factor expression showed similar changes qualitatively.

Conclusions:

  • Monocyte recognition of LPS involves LBP and CD14.
  • rBPI23 effectively inhibits LPS-induced TF expression in monocytes.
  • Inhibition of LPS-induced TF by rBPI23 may offer a therapeutic strategy for sepsis-related intravascular coagulation.